Than individuals.This isn’t necessarily a good thing. There was already a program in place that allowed terminally ill patients to access experimental/investigational drugs as a last resort: the Expanded Access program also “compas sionate use”) of the FDA. It differs from the RTT legislation because it required oversight from the FDA (including of the treatment plan and informed consent) as well as reporting of any adverse events that occurred. As 99% of EA requests are granted by the FDA (and review procedures can be expedited emergency. RTT doesn’t really expand access to these drugs, it removes oversight by the FDA, and it also removes liabili companies.
BUY IT:
Nhận xét
Đăng nhận xét